Boston Scientific accounts are for healthcare professionals only.
(See full prescribing information, including boxed warning and information for professionals and healthcare institutions. The Prescribing Information is available from the FDA.)
JND Therapeutics, Inc. is the U.S. distributor of Floxuridine for Injection, USP. Floxuridine for Injection, USP is a lyophilized powder for reconstitution intended for intra-arterial infusion only.
BOXED WARNING: It is recommended that floxuridine be given only by or under the supervision of a qualified physician who is experienced in cancer chemotherapy and intra-arterial drug therapy and is well versed in the use of potent antimetabolites.
Product information
- Generic name: Floxuridine for Injection, USP
- Product type: Lyophilized powder
- Description: Sterile, nonpyrogenic, white to off-white lyophilized powder for reconstitution
- Strength: 500 mg per vial
- Container: 5 mL vial
- Route of administration: Intra-arterial infusion only
- NDC: 81643-9270-1
- Storage: Store sterile powder at 68°F to 77°F (20°C to 25°C). Reconstituted vials should be storedunder refrigeration at 36°F to 46°F (2°C to 8°C) for not more than 2 weeks.
Medical information and adverse event reporting
For drug-specific medical information or to report suspected adverse reactions related to Floxuridine forInjection, USP, contact the approved medical information channel and adverse event reporting contacts.
Medical information:
Email: us.hikma@primevigilance.com
Adverse event reporting:
Email: PV@hikma.com
You may also report adverse events to the FDA at 1-800-FDA-1088 or via MedWatch.
Ordering information
Ordering information is intended for healthcare professionals and healthcare institutions only. To request ordering support for Floxuridine for Injection, USP, contact Customer Care.
Phone: 1-855-971-8346
Email: BSCemailordersUS2@bsci.com
Hours: Monday through Friday, 8:30 a.m. to 6 p.m. ET (excluding major U.S. national holidays)